| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | PRF-110 Post-operative pain (bunionectomy) | Phase 3 | — | Small Molecules | - | ||
Phase 3 data readout example | PRF-110 Post-operative pain (bunionectomy) | Phase 3 | — | Small Molecules | - | ||
Phase 3 data readout example | PRF-110 Post-operative pain (bunionectomy) | Phase 3 | — | Small Molecules | - |
Recent Updates
Recently added Catalysts
PRF Technologies Ltd.$1.45
-0.14 (-8.75%)
Market Cap
1.26 M
EPS
-8.49
P/E Ratio
-
Value Trade
863.17 K
-6.88 %
Week
-40.64 %
1 Month
-54.15 %
3 Month
-64.46 %
6 Month
-99.95 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
201.79 K
52 Week Range
1.28 - 17.95
% held by Insiders
0 %
% held by Institutions
9.48 %
Enterprise Value
-2.14 M
Total Shares
844.46 K
Short %
40.97 %
Float Shares
764.23 K
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRFX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
PRFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PRFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PRFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PRFX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PRFX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PRFXInvestor Presentation July 2022 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs a
Investor Presentation July 2022 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs and intentions . Forward - looking statements can be identif
Read more →PRFXPainReform Announces $6.0 Million Private Placement
PainReform Announces $6.0 Million Private Placement HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics,
Read more →PRFXNOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2021 To the shareholders of PainReform Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of the sharehol
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2021 To the shareholders of PainReform Ltd.: Notice is hereby given that an Extraordinary General Meeting (the "Meeting") of the shareholders of PainReform Ltd. (the "Company") will be held at the offic
Read more →PRFXPainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations HERZLIYA, Israel - January 6, 2021 - PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of established th
Read more →PRFXInvestor Presentation January 2021 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, belief
Investor Presentation January 2021 2 PainReform Ltd. | www.painreform.com Post Operative Pain Management Forward - Looking Statements This presentation contains forward - looking statements about our expectations, beliefs and intentions . Forward - looking statements can be iden
Read more →PRFXPainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 Reports steady progress towards start of Phase 3 trial
PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110 Reports steady progress towards start of HERZLIYA, Israel - January 4, 2021 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty
Read more →PRFXPainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer Israel - November 23, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of e
Read more →PRFXPainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors
PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors November 11, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation o
Read more →PRFXPainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors HERZLIYA, Israel - November XX, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a
PainReform Welcomes Senior Pharmaceutical Venture Capitalist Augustine Lawlor to Board of Directors November XX, 2020 - PainReform Ltd. (NasdaqCM: PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of establish
Read more →PRFXPainReform Highlights Surgical Advantages of PRF-110 Studies demonstrate unique benefits of PRF-100 beyond analgesic activity PRF-110 addresses potential concerns in the local administration of anesthetic related to woun
PainReform Highlights Surgical Advantages Studies demonstrate unique benefits of PRF-100 beyond analgesic activity PRF-110 addresses potential concerns in the local administration of anesthetic related to wound healing and suture integrity that are commonly involved in surgi
Read more →PRFXPAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2020 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Balance Sheets 2 Condensed Statements of Comprehensive Loss 3 Condensed Statement of Changes in
FINANCIAL STATEMENTS DOLLARS IN THOUSANDS Page Condensed Balance Sheets 2 Condensed Statements of Comprehensive Loss 3 Condensed Statement of Changes in Convertible Preferred Shares and Shareholders' Deficit 4 Condensed Statements of Cash Flows 5 Notes to Condensed Financial S
Read more →Competitive Position
How PRFX ranks across every disease it competes inCompetitive Position is a premium feature
See how PRFX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial